MedTrace Logo

Efficacy and Safety of MEDI3506 in Adult Subjects With Atopic Dermatitis

NCT04212169 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 148

Last updated 2023-09-28

Study results available
· View outcomes & findings →

Summary

This is a research study to determine the efficacy and safety of investigational drug MEDI3506 for the treatment of adult subjects with Atopic Dermatitis.

Conditions

Interventions

DRUG

MEDI3506

multiple doses

DRUG

Placebo

multiple doses

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-09
Primary Completion
2022-07-21
Completion
2022-09-20
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Germany
  • Poland
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04212169 on ClinicalTrials.gov